Grant of Interim Extension of the Term of U.S. Patent No. 4,971,802; MIFAMURTIDE, 58649 [E7-20372]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 199 / Tuesday, October 16, 2007 / Notices
October 16—Windward Passage
Hotel, Charlotte Amalie, St. Thomas,
USVI.
October 17—Buccaneer Hotel,
Christiansted, St Croix, USVI.
October 23—Pierre Hotel, De Diego
Avenue, San Juan, PR.
October 24—Ponce Golf and Casino
Resort, 1150 Caribe Avenue, Ponce, PR.
October 25—Mayaguez Holiday Inn,
2701 Highway #2, Mayaguez, PR.
Dated: October 11, 2007.
Tracey L. Thompson,
Acting Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. E7–20322 Filed 10–15–07; 8:45 am]
BILLING CODE 3510–22–S
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2007–0037]
Authority: 16 U.S.C. 1801 et seq.
Dated: October 11, 2007.
Alan D. Risenhoover,
Director, Office of Sustainable Fisheries,
National Marine Fisheries Service.
[FR Doc. 07–5107 Filed 10–11–07; 4:13 pm]
BILLING CODE 3510–22–P
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
RIN: 0648–XD37
North Pacific Fishery Management
Council; Public Meeting
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
AGENCY:
ACTION:
Notice of a public meeting.
The meeting will be held on
November 2, 2007, from 9 a.m. to 2 p.m.
DATES:
The meeting will be held at
the Hawthorn Suites, 1110 West 8th
Avenue, Anchorage, AK.
Council address: North Pacific
Fishery Management Council, 605 W.
4th Ave., Suite 306, Anchorage, AK
99501–2252.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Diana Stram, Council staff; telephone:
(907) 271–2809
The
Committee will discuss salmon bycatch
cap formulation alternatives for Bering
Sea and Aleutian Islands trawl fisheries
and develop recommendations.
SUPPLEMENTARY INFORMATION:
mmaher on PROD1PC70 with NOTICES
Special Accommodations
This meeting is physically accessible
to people with disabilities. Requests for
sign language interpretation or other
auxiliary aids should be directed to Gail
Bendixen at (907) 271–2809 at least 7
working days prior to the meeting date.
04:12 Oct 16, 2007
Jkt 214001
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a one-year interim extension of the term
of U.S. Patent No. 4,971,802.
FOR FURTHER INFORMATION CONTACT: Raul
Tamayo by telephone at (571) 272–7728;
by mail marked to his attention and
addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to his attention at
(571) 273–7728, or by e-mail to
Raul.Tamayo@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On August 8, 2007, IDM Pharma,
agent/licensee of patent owner Novartis,
timely filed an application under 35
U.S.C. 156(d)(5) for an interim extension
of the term of U.S. Patent No. 4,971,802.
Claims of the patent cover the product
Mifamurtide having the active
ingredient muramyl tripeptide
phosphatidyl ethanolamine. The
application indicates, and the Food and
Drug Administration has confirmed,
that a New Drug Application for the
human drug product Mifamurtide has
been filed and is currently undergoing
regulatory review before the Food and
Drug Administration for permission to
market or use the product commercially.
Review of the application indicates
that, except for permission to market or
SUPPLEMENTARY INFORMATION:
SUMMARY: The North Pacific Fishery
Management Council (Council) Salmon
Bycatch Workgroup will meet in
Anchorage, AK.
VerDate Aug<31>2005
Grant of Interim Extension of the Term
of U.S. Patent No. 4,971,802;
MIFAMURTIDE
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
58649
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because it is
apparent that the regulatory review
period will continue beyond the
expiration date of the patent (November
20, 2007), interim extension of the
patent term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,971,802 is granted for a period of one
year from the expiration date of the
patent, i.e., until November 20, 2008.
Dated: October 4, 2007.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E7–20372 Filed 10–15–07; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF ENERGY
Federal Energy Regulatory
Commission
[IC07–574–001, FERC–574]
Commission Information Collection
Activities, Proposed Collection;
Comment Request; Extension
October 4, 2007.
Federal Energy Regulatory
Commission.
ACTION: Notice.
AGENCY:
SUMMARY: In compliance with the
requirements of section 3507 of the
Paperwork Reduction Act of 1995, 44
U.S.C. 3507, the Federal Energy
Regulatory Commission (Commission)
has submitted the information
collection described below to the Office
of Management and Budget (OMB) for
review and extension of this
information collection requirement. Any
interested person may file comments
directly with OMB and should address
a copy of those comments to the
Commission as explained below. The
Commission did not receive any
comments in response to an earlier
Federal Register notice of May 29, 2007
(72 FR 29489–29490) and has made this
notification in its submission to OMB.
Copies of the submission were also
submitted to the commenters.
DATES: Comments on the collection of
information are due by November 13,
2007.
ADDRESSES: Address comments on the
collection of information to the Office of
Management and Budget, Office of
E:\FR\FM\16OCN1.SGM
16OCN1
]]>Agencies
[Federal Register Volume 72, Number 199 (Tuesday, October 16, 2007)]
[Notices]
[Page 58649]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-20372]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2007-0037]
Grant of Interim Extension of the Term of U.S. Patent No.
4,971,802; MIFAMURTIDE
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term Extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension
of the term of U.S. Patent No. 4,971,802.
FOR FURTHER INFORMATION CONTACT: Raul Tamayo by telephone at (571) 272-
7728; by mail marked to his attention and addressed to the Commissioner
for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA
22313-1450; by fax marked to his attention at (571) 273-7728, or by e-
mail to Raul.Tamayo@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On August 8, 2007, IDM Pharma, agent/licensee of patent owner
Novartis, timely filed an application under 35 U.S.C. 156(d)(5) for an
interim extension of the term of U.S. Patent No. 4,971,802. Claims of
the patent cover the product Mifamurtide having the active ingredient
muramyl tripeptide phosphatidyl ethanolamine. The application
indicates, and the Food and Drug Administration has confirmed, that a
New Drug Application for the human drug product Mifamurtide has been
filed and is currently undergoing regulatory review before the Food and
Drug Administration for permission to market or use the product
commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review
period will continue beyond the expiration date of the patent (November
20, 2007), interim extension of the patent term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,971,802 is granted for a period of one year from the
expiration date of the patent, i.e., until November 20, 2008.
Dated: October 4, 2007.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. E7-20372 Filed 10-15-07; 8:45 am]
BILLING CODE 3510-16-P
